BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Colorectal Cancer (CRC)

June 13, 2022

First- and particularly second-line metastatic CRC have become very crowded treatment settings, with multiple combinations of chemotherapies and targeted agents competing for the same patient subsets. 

Avastin, the first targeted agent launched in the indication, is the traditional standard of care and remains widely prescribed in both first- and second-line disease and across tumor profiles. However, the branded drug is approaching the end of its lifecycle and the recent launches of bevacizumab biosimilars will significantly erode its market share. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Colorectal Cancer (CRC)
Back to the top Back to the top